extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
2db3bb522b
commit
f94d0f27b9
6 changed files with 65 additions and 1 deletions
|
|
@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP
|
|||
|
||||
The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
Medicare-specific modeling shows net savings of $715M over 10 years when multi-indication benefits (T2D, obesity, MASH) are comprehensively accounted for, with T2D savings ($892M) exceeding obesity costs ($205M). This challenges the universal 'inflationary through 2035' framing by demonstrating that risk-bearing payers capturing both costs and downstream savings can achieve cost-neutrality or savings, even as system-level spending increases.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -48,6 +48,12 @@ Phase 3 trial shows semaglutide 2.4mg achieves 62.9% resolution of steatohepatit
|
|||
|
||||
FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89) and 18% lower risk of major cardiovascular events in a kidney-focused trial. The cardiovascular benefits emerged as secondary endpoints in a study designed for kidney outcomes, supporting the multi-organ protection thesis. Separate analysis in Nature Medicine showed additive benefits when combined with SGLT2 inhibitors.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
10-year Medicare modeling quantifies multi-organ protection: 38,950 CV events avoided, 6,180 deaths prevented, with per-subject savings of $14,431 (T2D), $2,074 (CKD), and $1,512 (CV events). Per 100,000 subjects: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -34,6 +34,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
|
|||
|
||||
FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), with annual eGFR decline slowed by 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early at prespecified interim analysis due to efficacy. FDA subsequently expanded semaglutide indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, published in NEJM.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
Medicare modeling confirms CKD savings of $2,074 per subject over lifetime, contributing $28M in MASH-related savings over 10 years. While smaller than T2D savings ($892M) or CV savings, CKD cost avoidance is a measurable component of multi-indication value.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -37,6 +37,12 @@ The composition of spending shifts dramatically: less on chronic disease managem
|
|||
|
||||
(extend) The Medicare trust fund fiscal pressure adds a constraint layer to the cost curve dynamics. While new capabilities create upward cost pressure through expanded treatment populations, the trust fund exhaustion timeline (now 2040, accelerated from 2055 by tax policy changes) creates a hard fiscal boundary. The convergence of demographic pressure (working-age to 65+ ratio declining to 2.2:1 by 2055), MA overpayments ($1.2T/decade), and reduced tax revenues means automatic 8-10% benefit cuts starting 2040 unless structural reforms occur. This fiscal ceiling will force coverage and payment decisions in the 2030s independent of technology trajectories, potentially constraining the cost curve expansion that new capabilities would otherwise enable.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
GLP-1 case study demonstrates the payment structure dependency: system-level spending increases (cost curve bends up) while risk-bearing payer spending can decrease (Medicare saves $715M) because comprehensive multi-indication access under capitation allows a single entity to capture both costs and savings. This reveals that 'cost curve bending' is not monolithic but varies by payment model.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,24 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-06-01
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: paper
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -39,3 +43,15 @@ Key findings:
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity
|
||||
EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare semaglutide modeling projects $715M net savings over 2026-2035 (range: $412M-$1.04B)
|
||||
- T2D-related savings: $892M over 10 years
|
||||
- Obesity-related costs: $205M over 10 years
|
||||
- MASH-related savings: $28M over 10 years
|
||||
- 38,950 cardiovascular events avoided over 10 years
|
||||
- 6,180 deaths avoided (CV + CKD/MASH)
|
||||
- Average per-subject lifetime treatment costs: $47,353
|
||||
- Per-subject savings: $14,431 (T2D), $2,074 (CKD), $1,512 (CV events)
|
||||
- Per 100,000 subjects: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
|
||||
|
|
|
|||
Loading…
Reference in a new issue